QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
by Zacks Equity Research
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China
by Zacks Equity Research
QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.
Are Investors Undervaluing PetIQ (PETQ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights Boyd Gaming, Expeditors International of Washington, QuidelOrtho, LPL Financial and Cboe Global Markets
by Zacks Equity Research
Boyd Gaming, Expeditors International of Washington, QuidelOrtho, LPL Financial and Cboe Global Markets have been highlighted in this Screen of The Week article.
5 Stocks With Solid Sales Growth to Fight Economic Slowdown
by Swayta Shah
Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Boyd Gaming (BYD), Expeditors International (EXPD), QuidelOrtho (QDEL), LPL Financial (LPLA) and Cboe Global (CBOE), which are recording top-line growth.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Zacks.com featured highlights include Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors
by Zacks Equity Research
Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors are part of the Zacks Screen of the Week article.
5 Stocks With Solid Sales Growth to Navigate Volatile Markets
by Swayta Shah
Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Crocs (CROX), Unum (UNM), QuidelOrtho (QDEL), LPL Financial (LPLA) and Clean Harbors (CLH), which are witnessing top-line growth.
3 Medical Products Stocks Navigating Industry Challenges (Revised)
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Is QuidelOrtho (QDEL) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics
by Zacks Equity Research
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Are Investors Undervaluing PetIQ (PETQ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights Conagra, Cboe Global Markets, QuidelOrtho, American Electric Power Company and Clean Harbors
by Zacks Equity Research
Conagra, Cboe Global Markets, QuidelOrtho, American Electric Power Company and Clean Harbors have been highlighted in this Screen of The Week article.
5 Stocks With Robust Sales Growth to Combat Recession Fears
by Swayta Shah
Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Conagra Brands (CAG), Cboe Global Markets (CBOE), QuidelOrtho (QDEL), American Electric Power (AEP) & Clean Harbors (CLH) that are recording top-line growth.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.